AI Article Synopsis

  • Perioperative ischemia/reperfusion (I/R) injury during liver transplantation can lead to early allograft dysfunction, impacting liver and other organs like kidneys and lungs.
  • This study investigates whether dexmedetomidine (DEX), used as an anesthesia adjuvant, can reduce early allograft dysfunction and primary graft non-function by providing organ protection during liver transplants.
  • A total of 200 participants aged 18-65 will be randomized into two groups: one receiving DEX and the other a placebo, while other anesthesia protocols remain consistent, assessing DEX's effects on liver, renal, and lung functions.

Article Abstract

Background: Perioperative ischemia/reperfusion (I/R) injury during liver transplantation is strongly associated with early allograft dysfunction (EAD), graft loss, and mortality. Hepatic I/R injury also causes remote damage to other organs including the renal and pulmonary systems. Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist which is used as an adjuvant to general anesthesia, has been shown in preclinical studies to provide organ protection by ameliorating the effects of I/R injury in a range of tissues (including the liver). However, prospective clinical evidence of any potential benefits in improving outcomes in liver transplantation is lacking. This study aimed to verify the hypothesis that the application of dexmedetomidine during the perioperative period of liver transplantation can reduce the incidence of EAD and primary graft non-function (PNF). At the same time, the effects of dexmedetomidine application on perioperative renal function and lung function were studied.

Methods: This is a prospective, single-center, randomized, parallel-group study. Two hundred participants (18-65 years) scheduled to undergo liver transplantation under general anesthesia will be included in this study. For participants in the treatment group, a loading dose of DEX will be given after induction of anesthesia (1 μg/kg over 10 min) followed by a continuous infusion (0.5 μg/kg /h) until the end of surgery. For participants in the placebo group, an equal volume loading dose of 0.9% saline will be given after the induction of anesthesia followed by an equal volume continuous infusion until the end of surgery. All other supplements, e.g., opioids, sedatives, and muscle relaxant, will be identical in both arms and administered according to routine clinical practice.

Discussion: The present trial will examine whether DEX confers organoprotective effects in the liver, in terms of reducing the incidence of EAD and PNF in orthotopic liver transplantation recipients.

Trial Registration: ClinicalTrials.gov NCT03770130. Registered on 10 December 2018. https://clinicaltrials.gov/ct2/show/NCT03770130.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317895PMC
http://dx.doi.org/10.1186/s13063-020-04497-7DOI Listing

Publication Analysis

Top Keywords

liver transplantation
24
i/r injury
12
early allograft
8
allograft dysfunction
8
liver
8
general anesthesia
8
incidence ead
8
study participants
8
loading dose
8
will induction
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!